New Fine Pleomorphic Calcifications in a 49-Year-Old With Dense Breasts
A 49-year-old woman attends for her second screening mammogram, performed with digital breast tomosynthesis. She has no breast symptoms, no family history, and a body mass index of 31. Breast density is heterogeneously dense (ACR category C). The right mediolateral oblique and craniocaudal views show a new 14 mm cluster of fine pleomorphic calcifications in the upper outer quadrant, 6 cm from the nipple, with no associated mass or architectural distortion. No calcifications were present on the prior study two years ago. Targeted ultrasound at the site is negative. The screening radiologist has 20 minutes before the next screening batch and asks whether this can be managed with a 6-month short-interval follow-up, given that the patient is very anxious about needles and the ultrasound was normal.
1. Assign a BI-RADS category and define the next step, explaining why follow-up would be inappropriate and why an ultrasound-guided approach is unsuitable.
Read the worked answer
Category: BI-RADS 4C (suspicious), driven by new fine pleomorphic calcifications. Morphology alone is suspicious; new appearance relative to a prior study adds further weight. Reported positive predictive values for fine pleomorphic calcifications cluster in the 20-60% range.
Why 6-month follow-up is wrong:
- Short-interval follow-up is reserved for probably benign findings (BI-RADS 3) with a malignancy rate under about 2%. A new pleomorphic cluster is far above that, and a 6-month delay could allow a ductal carcinoma in situ to become invasive or to grow beyond breast-conserving surgery.
- The patient's needle anxiety is a real issue but is managed with counselling, local anaesthetic, reassurance and, if needed, anxiolysis - not by deferring diagnosis.
Correct next step: stereotactic vacuum-assisted biopsy
- Use a 9-11 gauge vacuum-assisted device, with the patient prone or seated, targeting the calcifications using scout and paired stereo images.
- Place a clip at the end of the procedure and obtain a specimen radiograph to confirm that calcifications have actually been retrieved. Calcification retrieval is the single most important quality metric; a non-representative specimen is worse than no biopsy.
- Post-biopsy two-view mammogram to document clip position.
- Ultrasound guidance is not appropriate because there is no sonographic correlate; attempting it is a common cause of inadequate sampling.
Send for histology with radiographic-pathological correlation; if the histology does not explain the calcifications, proceed to wire-localised excision or repeat larger sampling.
2. Histology returns atypical ductal hyperplasia only. What are the implications, and how do they differ from a diagnosis of low-grade ductal carcinoma in situ?
Read the worked answer
Atypical ductal hyperplasia on core biopsy:
- This is a high-risk lesion, and upgrade to carcinoma at excision is reported in roughly 10-30% of cases (higher when the lesion is larger, when multiple foci are present, or when the sampling is limited).
- Standard practice is therefore excision, either wire-localised surgical excision or, in selected cases in some centres, vacuum-assisted complete excision with imaging follow-up. Given that the original indication was a calcification cluster, surgical excision with specimen radiography is the safest option here.
- If excision confirms ADH alone, the patient enters a high-risk surveillance pathway and should be offered a discussion of endocrine chemoprevention (tamoxifen, raloxifene or an aromatase inhibitor) balancing menopausal status, uterine and thromboembolic risk.
If instead the result were low-grade DCIS:
- Management is driven by size, grade, margins and extent. Breast-conserving surgery with clear margins (typically 2 mm for DCIS) plus whole-breast radiotherapy is standard; mastectomy is reserved for extensive or multifocal disease or patient preference.
- Sentinel lymph node biopsy is generally not required for DCIS treated by breast conservation, but is done when mastectomy is planned or when there is suspicion of invasion.
- Endocrine therapy reduces ipsilateral recurrence risk; the absolute benefit is modest and should be discussed.
In both scenarios, radiographic-pathological correlation is essential before the result is accepted.
3. The patient asks whether she should have MRI or extra screening because of her dense breasts. How do you answer, and what is the role of MRI in this specific situation?
Read the worked answer
In the immediate work-up: MRI has no role in the evaluation of calcifications. DCIS is frequently non-enhancing or only faintly enhancing, so a normal MRI is falsely reassuring, and MRI tends to overestimate extent, potentially pushing a patient towards mastectomy unnecessarily. Contrast-enhanced mammography or further mammographic views would be more defensible, but the biopsy is the decisive step.
After a diagnosis, MRI may be used selectively for extent assessment when breast conservation is being considered and mammography underestimates disease, or when there is a discrepancy between imaging and histology.
On dense-breast supplemental screening:
- She is already having tomosynthesis, which improves cancer detection in dense breasts compared with 2D alone and is a reasonable baseline.
- Supplemental ultrasound increases cancer detection in dense breasts but also false positives and benign biopsies. Abbreviated MRI detects substantially more cancers, particularly node-negative invasive disease, but has a high recall rate and cost.
- MRI screening is clearly indicated for high lifetime risk (generally 20-25% or more by a validated model), known BRCA or other high-penetrance mutations, chest irradiation at a young age, and some other syndromes. She has no family history and does not currently qualify on risk grounds.
- The honest answer is that density is a population-level risk factor and a masking factor, not by itself an automatic MRI indication, and that the appropriate decision depends on a formal risk assessment discussed with her clinician.